What do systematic reviews say?

Change in VO2 peak during maximal exercise · adolescents and adults with cystic fibrosis

Adherence · adults and children with cystic fibrosis

Need for extra antibiotics (days) · adults and children with cystic fibrosis

Quality of life · adolescents and adults with cystic fibrosis

Adherence · adolescents and adults with cystic fibrosis

Need for extra antibiotics (days) · adolescents and adults with cystic fibrosis

Change in VO2 peak during maximal exercise · children and young adults with CF

Cardiovascular events · Adults without diabetes or CVD

All‐cause mortality · Adults without diabetes or CVD

Time to mature · CKD patients who underwent AVF creation

Dialysis efficacy indicator · CKD patients who underwent AVF creation

Vascular access function · CKD patients who underwent AVF creation

Adverse events · CKD patients who underwent AVF creation

Weight loss of at least 5% at ≥ 12 months ‐ not measured · overweight and obese participants without T2DM (weight‐reducing phase followed by weight maintenance phase)

Cardiovascular mortality ‐ not measured · overweight and obese participants without T2DM (weight‐reducing phase followed by weight maintenance phase)

Constipation at 3 to < 12 months ‐ not measured · overweight and obese participants without T2DM (weight‐reducing phase followed by weight maintenance phase)

Cardiovascular mortality ‐ not measured · overweight and obese participants with T2DM (weight‐reducing phase only)

Weight loss of at least 5% at ≥ 12 months ‐ not measured · overweight and obese participants with T2DM (weight‐reducing phase followed by weight‐maintenance phase)

Cardiovascular mortality ‐ not measured · overweight and obese participants with T2DM (weight‐reducing phase followed by weight‐maintenance phase)

Constipation at 3 to < 12 months ‐ not measured · overweight and obese participants with T2DM (weight‐reducing phase followed by weight‐maintenance phase)